Special considerations on the management of Latino patients with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 969-979

  Gonzalez, Amparo B ^a   Salas, Daniela ^a   Umpierrez, Guillermo E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disparity; Ethnicity; Hispanic; Latino; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; METFORMIN;

CULTURAL FACTOR; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH DISPARITY; HISPANIC; HUMAN; INCIDENCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT CARE; PREVALENCE; REVIEW;

DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; PRIMARY HEALTH CARE; PUBMED; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 79954506125     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.563505     Document Type: Review

References (136)

1. Centers for Disease Control and Prevention (CDC). State-specific incidence of diabetes among adults-participating states, 1995-1997 and 2005-2007. MMWR Morb Mortal Wkly Rep 2008;57:1169-73.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53. (Pubitemid 38579764)
3. Economic costs of diabetes in the U.S. in 2007. Diabetes care 2008; 31:596-615.
4. Huang ES, Basu A, O'Grady M, et al. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care 2009;32:2225-9.
5. US Census Bureau Newsroom Report, August 14, 2008. An Older and More Diverse Nation by Midcentury. CB08-123. Available at: http://www.census.gov/ newsroom/releases/archives/population/cb08-123.html [Last accessed 7 August 2010].
6. US Census Bureau. Facts for Features-Hispanic Heritage Month 2009. CB09-FF17 Updated Sept 14, 2009. Available at: http://wwwcensusgov/newsroom/ releases/archives/facts-for-features-special-editions/cb09- ff17html [Last accessed 7 August 2010].
7. Sanchez-Castillo CP, Velazquez-Monroy O, Berber A, et al. Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. Obes Res 2003;11:442-51. (Pubitemid 41151634)
8. National Center for Health Statistics. Health, United States, 2009: With Special Feature on Medical Technology. Hyattsville, MD, 2010.
9. Davis JN, Kelly LA, Lane CJ, et al. Randomized control trial to improve adiposity and insulin resistance in overweight Latino adolescents. Obesity 2009;17:1542-8.
10. Davis JN, Ventura EE, Shaibi GQ, et al. Interventions for improving metabolic risk in overweight Latino youth. Int J Pediatr Obes 2010;5:451-5.
11. Lawrence JM, Mayer-Davis EJ, Reynolds K, et al. Diabetes in Hispanic American youth: prevalence, incidence, demographics, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care 2009; 32(Suppl. 2):S123-32.
12. Goran MI, Lane C, Toledo-Corral C, et al. Persistence of pre-diabetes in overweight and obese Hispanic children: association with progressive insulin resistance, poor beta-cell function, and increasing visceral fat. Diabetes 2008;57:3007-12.
13. Booth GL, Hux JE. Relationship between avoidable hospitalizations for diabetes mellitus and income level. Arch Intern Med 2003;163:101-6. (Pubitemid 36091607)
14. Kanjilal S, Gregg EW, Cheng YJ, et al. Socioeconomic status and trends in disparities in 4 major risk factors for cardiovascular disease among US adults, 1971-2002. Arch Intern Med 2006;166:2348-55. (Pubitemid 44833360)
15. Walsh MG, Zgibor J, Songer T, et al. The socioeconomic correlates of global complication prevalence in type 1 diabetes (T1D): a multinational comparison. Diabet Res Clin Pract 2005;70:143-50. (Pubitemid 41368062)
16. Whitford DL, Griffin SJ, Prevost AT. Influences on the variation in prevalence of type 2 diabetes between general practices: practice, patient or socioeconomic factors? Br J Gen Pract 2003;53:9-14. (Pubitemid 36040597)
17. Evans JM, Newton RW, Ruta DA, et al. Socio-economic status, obesity and prevalence of Type 1 and Type 2 diabetes mellitus. Diabet Med 2000; 17:478-80. (Pubitemid 30471344)
18. Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis 2009;19:288-92.
19. Fisher-Hoch SP, Rentfro AR, Salinas JJ, et al. Socioeconomic status and prevalence of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004-2007. Preventing Chronic Disease;7:A53.
20. Flavin NE, Mulla ZD, Bonilla-Navarrete A, et al. Health insurance and the development of diabetic complications. South Med J 2009;102:805-9.
21. Sosa-Rubi SG, Galarraga O, Lopez-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull World Health Organ 2009;87:512-19.
22. Bowker SL, Mitchell CG, Majumdar SR, et al. Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type 2 diabetes. CMAJ 2004;171:39-43. (Pubitemid 38925117)
23. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-9.
24. DeNavas-Walt C, Bernadette DP, Smith JC. U.S. Census Bureau, Current Population Reports, P60-236, Income, Poverty, and Health Insurance Coverage in the United States: 2008. Washington, DC: U.S. Government Printing Office, 2009.
25. Karter AJ, Ferrara A, Liu JY, et al. Ethnic disparities in diabetic complications in an insured population. JAMA 2002;287:2519-27. (Pubitemid 34517197)
26. Crespo CJ, Smit E, Carter-Pokras O, et al. Acculturation and leisure-time physical inactivity in Mexican American adults: results from NHANES III, 1988-1994. Am J Pub Health 2001;91:1254-7. (Pubitemid 32708865)
27. Bermudez OI, Falcon LM, Tucker KL. Intake and food sources of macronutrients among older Hispanic adults: association with ethnicity, acculturation, and length of residence in the United States. J Am Diet Assoc 2000; 100:665-73.
28. Unger JB, Reynolds K, Shakib S, et al. Acculturation, physical activity, and fast-food consumption among Asian-American and Hispanic adolescents. J Community Health 2004;29:467-81. (Pubitemid 41215289)
29. Dixon LB, Sundquist J, Winkleby M. Differences in energy, nutrient, and food intakes in a US sample of Mexican-American women and men: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2000;152:548-57.
30. Gans KM, Burkholder GJ, Risica PM, Lasater TM. Baseline fat-related dietary behaviors of white, Hispanic, and black participants in a cholesterol screening and education project in New England. J Am Diet Assoc 2003;103(6):699- 706; discussion 706. (Pubitemid 38375907)
31. Haffner SM, D'Agostino R, Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45:742-8.
32. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 1997; 46:63-9. (Pubitemid 27009951)
33. Kirk JK, Passmore LV, Bell RA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 2008;31:240-6. (Pubitemid 351213329)
34. Boltri JM, Okosun IS, Davis-Smith M, et al. Hemoglobin A1c levels in diagnosed and undiagnosed black, Hispanic, and white persons with diabetes: results from NHANES 1999-2000. Ethn Dis 2005;15:562-7. (Pubitemid 41645121)
35. Katusic D, Tomic M, Jukic T, et al. Obesity-a risk factor for diabetic retinopathy in type 2 diabetes? Collegium Antropologicum 2005; 29(Suppl 1):47-50. (Pubitemid 41265098)
36. Raman R, Rani PK, Gnanamoorthy P, et al. Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8). Acta Diabetol 2010; 47:209-15.
37. Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diabetes Rep 2007;7:449-53. (Pubitemid 350284976)
38. Morales E, Valero MA, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41:319-27. (Pubitemid 36152449)
39. Koch M, Beien A, Fussha Ller A, et al. Impact of age, body mass index, insulin resistance and proteinuria on the kidney function in obese patients with Type 2 diabetes and renal insufficiency. Clin Nephrol 2008;69:10-17.
40. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of nondiabetic chronic kidney disease: a retrospective cohort study. Nephron 2009; 113:c16-23.
41. Verhave JC, Hillege HL, Burgerhof JG, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004; 256:324-30. (Pubitemid 39304344)
42. de Jong PE, Verhave JC, Pinto-Sietsma SJ, et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26(Suppl. 4):S21-4. (Pubitemid 36071967)
43. Bergstrom B, Lilja B, Osterlin S, et al. Autonomic neuropathy in non-insulin dependent (type II) diabetes mellitus. Possible influence of obesity. J Intern Med 1990;227:57-63. (Pubitemid 20019822)
44. Straub RH, Thum M, Hollerbach C, et al. Impact of obesity on neuropathic late complications in NIDDM. Diabetes Care 1994;17:1290-4. (Pubitemid 24324973)
45. McDaid EA, Monaghan B, Parker AI, et al. Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. Diabetes Care 1994; 17:1422-7. (Pubitemid 24369726)
46. Szelag B, Wroblewski M, Castenfors J, et al. Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes. Diabetes Care 1999;22:1907-8. (Pubitemid 29521884)
47. Valensi P, Paries J, Attali JR. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications-the French multicenter study. Metabolism 2003;52:815-20. (Pubitemid 36949541)
48. Howard G, Anderson R, Sorlie P, et al. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke 1994;25:2120-5. (Pubitemid 24338361)
49. Wild SH, Laws A, Fortmann SP, et al. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. Ann Epidemiol 1995;5:432-9.
50. Goff Jr DC, Ramsey DJ, Labarthe DR, et al. Acute myocardial infarction and coronary heart disease mortality among Mexican Americans and non- Hispanic whites in Texas, 1980 through 1989. Ethn Dis 1993;3:64-9.
51. Sorlie PD, Backlund E, Johnson NJ, et al. Mortality by Hispanic status in the United States. JAMA 1993;270:2464-8. (Pubitemid 23342296)
52. Liao Y, Cooper RS, Cao G, et al. Mortality from coronary heart disease and cardiovascular disease among adult U.S. Hispanics: findings from the National Health Interview Survey (1986 to 1994). J Am Coll Cardiol 1997; 30:1200-5. (Pubitemid 27501435)
53. Becker TM, Wiggins C, Key CR, et al. Ischemic heart disease mortality in Hispanics, American Indians, and non-Hispanic whites in New Mexico, 1958-1982. Circulation 1988;78:302-9.
54. Swenson CJ, Trepka MJ, Rewers MJ, et al. Cardiovascular disease mortality in Hispanics and non-Hispanic whites. Am J Epidemiol 2002;156:919-28. (Pubitemid 35304072)
55. Goran MI. Ethnic-specific pathways to obesity-related disease: the Hispanic vs. African-American paradox. Obesity 2008;16:2561-5.
56. Hunt KJ, Williams K, Resendez RG, et al. All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the 'Hispanic Paradox'. Diabetes Care 2002;25:1557-63. (Pubitemid 41071111)
57. Lerman-Garber I, Villa AR, Caballero E. Diabetes and cardiovascular disease. Is there a true Hispanic paradox? Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2004;56:282-96. (Pubitemid 39232125)
58. Hertz RP, Unger AN, Ferrario CM. Diabetes, hypertension, and dyslipidemia in Mexican Americans and non-Hispanic whites. Am J Prev Med 2006; 30:103-10. (Pubitemid 43184154)
59. Lee E, Candrilli SD, Roberts CS, et al. Regional differences in the prevalence, treatment and control of hypertension and dyslipidemia in US urban Hispanic populations participating in health screening events. Ethn Dis 2008;18:409-14.
60. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206. (Pubitemid 37430058)
61. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62. (Pubitemid 23335891)
62. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin- convertingenzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45. (Pubitemid 26114159)
63. Ravera M, Ratto E, Vettoretti S, et al. Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation. J Am Soc Nephrol 2005;16(Suppl. 1):S48-52. (Pubitemid 41725083)
64. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
65. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
66. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. (Pubitemid 38670018)
67. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
68. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555-65. (Pubitemid 36835100)
69. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252-6. (Pubitemid 28470337)
70. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005;365:939-46. (Pubitemid 41071427)
71. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
72. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-85.
73. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. (Pubitemid 351831356)
74. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005;16:2170-9. (Pubitemid 41716450)
75. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. (Pubitemid 351522739)
76. Hughes S. INVEST: Mortality hazard with lowest blood pressures in diabetics with CAD? 2010; Available from: http://www.theheart.org/article/ 1055859.do [Last accessed 15 December 2010].
77. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-421.
78. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52. (Pubitemid 37553153)
79. Standards of medical care in diabetes-2010. Diabetes Care;33(Suppl. 1): S11-61.
80. Executive summary: Standards of medical care in diabetes-2010. Diabetes Care;33(Suppl. 1):S4-10.
81. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-26. (Pubitemid 46058619)
82. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72. (Pubitemid 46052519)
83. Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr Pract 2006;12:193-222.
84. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl. 1):1-68.
85. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
86. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10. (Pubitemid 32064838)
87. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008: 12;358:2560-72. (Pubitemid 351831357)
88. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53. (Pubitemid 41817713)
89. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
90. Collins AJ, Foley RN, Herzog C, et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis 2009;53(1 Suppl.):S1-374.
91. Peralta CA, Shlipak MG, Fan D, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 2006; 17:2892-9. (Pubitemid 44484680)
92. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998;32:992-9. (Pubitemid 28551162)
93. Kottgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008;51:385-94. (Pubitemid 351273481)
94. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12. (Pubitemid 36043346)
95. Lora CM, Daviglus ML, Kusek JW, et al. Chronic kidney disease in United States Hispanics: a growing public health problem. Ethn Dis 2009; 19:466-72.
96. Kramer H, Palmas W, Kestenbaum B, et al. Chronic kidney disease prevalence estimates among racial/ethnic groups: the Multi-Ethnic Study of Atherosclerosis. Clin J Am Soc Nephrol 2008;3:1391-7.
97. Harris MI, Klein R, Cowie CC, et al. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A U.S. population study. Diabetes Care 1998; 21:1230-5. (Pubitemid 28365675)
98. Varma R, Torres M, Pena F, et al. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology 2004; 111:1298-306. (Pubitemid 38844824)
99. Chen JL, Luviano DM, Chen JC, et al. Comparison of diabetic retinopathy phenotype between Latinos and Blacks. J Diabetes Complications 2009; 23:371-5.
100. Sands ML, Shetterly SM, Franklin GM, et al. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997;20:322-9.
101. Young BA, Maynard C, Reiber G, et al. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care 2003;26:495-501. (Pubitemid 36929081)
102. Lavery LA, Armstrong DG, Wunderlich RP, et al. Diabetic foot syndrome: evaluating the prevalence and incidence of foot pathology in Mexican Americans and non-Hispanic whites from a diabetes disease management cohort. Diabetes Care 2003;26:1435-8. (Pubitemid 36929175)
103. Greenhagen RM, Johnson AR, Bevilacqua NJ. Smoking cessation: the role of the foot and ankle surgeon. Foot & Ankle Specialist 2010;3:21-8.
104. Flores G. Culture and the patient-physician relationship: achieving cultural competency in health care. J Pediatr 2000;136:14-23. (Pubitemid 30468551)
105. Gilmer TP, Philis-Tsimikas A, Walker C. Outcomes of Project Dulce: a culturally specific diabetes management program. Ann Pharmacother 2005; 39:817-22. (Pubitemid 40570658)
106. Racial and Ethnic Approaches to Community Health. Available at: http://www.cdc.gov/reach/index.htm [Last accessed 7 August 2010].
107. Two Feathers J, Kieffer EC, Palmisano G, et al. Racial and Ethnic Approaches to Community Health (REACH) Detroit partnership: improving diabetes-related outcomes among African American and Latino adults. Am J Public Health 2005;95:1552-60. (Pubitemid 41232948)
108. Metghalchi S, Rivera M, Beeson L, et al. Improved clinical outcomes using a culturally sensitive diabetes education program in a Hispanic population. Diabetes Educ 2008;34:698-706.
109. Duraski SA. Stroke prevention education in the Hispanic community. Rehabil Nurs 2006;31:5-9.
110. Brown SA, Hanis CL. Culturally competent diabetes education for Mexican Americans: the Starr County Study. The Diabetes Educator 1999;25:226-36.
111. McElmurry BJ, McCreary LL, Park CG, et al. Implementation, outcomes, and lessons learned from a collaborative primary health care program to improve diabetes care among urban Latino populations. Health Promot Pract 2009;10:293-302.
112. Lopez-Quintero C, Berry EM, Neumark Y. Limited English proficiency is a barrier to receipt of advice about physical activity and diet among Hispanics with chronic diseases in the United States. J Am Diet Assoc;110(5 Suppl.): S62-7.
113. Eamranond PP, Davis RB, Phillips RS, Wee CC. Patient-physician language concordance and lifestyle counseling among Spanish-speaking patients. J Immigr Minor Health 2009;11:494-8.
114. Campos C. Addressing cultural barriers to the successful use of insulin in Hispanics with type 2 diabetes. South Med J 2007;100:812-20. (Pubitemid 47356882)
115. Herndon E, Joyce L. Getting the most from language interpreters. Fam Pract Manag 2004;11:37-40.
116. Rustveld LO, Pavlik VN, Jibaja-Weiss ML, et al. Adherence to diabetes selfcare behaviors in English- and Spanish-speaking Hispanic men. Patient Prefer Adherence 2009;3:123-30.
117. Brown SA, Garcia AA, Kouzekanani K, et al. Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative. Diabetes Care 2002;25:259-68. (Pubitemid 41079619)
118. Osei-Assibey G, Kyrou I, Adi Y, et al. Dietary and lifestyle interventions for weight management in adults from minority ethnic/non-White groups: a systematic review. Obes Rev 2010 Nov;11(11):769-76.
119. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165-71.
120. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
121. West DS, Elaine Prewitt T, Bursac Z, et al. Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. Obesity 2008;16:1413-20. (Pubitemid 351770519)
122. Wadden TA, West DS, Neiberg RH, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity 2009;17:713-22.
123. Mau MK, Keawe'aimoku Kaholokula J, West MR, et al. Translating diabetes prevention into native Hawaiian and Pacific Islander communities: the PILI 'Ohana Pilot project. Prog Community Health Partnersh 2010;4:7-16.
124. Kramer MK, Kriska AM, Venditti EM, et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med 2009;37:505-11.
125. Matvienko OA, Hoehns JD. A lifestyle intervention study in patients with diabetes or impaired glucose tolerance: translation of a research intervention into practice. J Am Board Fam Med 2009;22:535-43.
126. Merriam PA, Tellez TL, Rosal MC, et al. Methodology of a diabetes prevention translational research project utilizing a community-academic partnership for implementation in an underserved Latino community. BMC Med Res Methodol 2009;9:20.
127. Whittemore R, Melkus G, Wagner J, et al. Translating the diabetes prevention program to primary care: a pilot study. Nursing Res 2009;58:2-12.
128. McBride PE, Einerson JA, Grant H, et al. Putting the Diabetes Prevention Program into practice: a program for weight loss and cardiovascular risk reduction for patients with metabolic syndrome or type 2 diabetes mellitus. J Nutr Health Aging 2008;12:745S-9S.
129. Ackermann RT, Finch EA, Brizendine E, et al. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008;35:357-63.
130. Standards of medical care in diabetes-2011. Diabetes Care 2011;34 (Suppl. 1):S11-61.
131. Thackeray R, Merrill RM, Neiger BL. Disparities in diabetes management practice between racial and ethnic groups in the United States. The Diabetes Educator 2004;30:665-75. (Pubitemid 39091139)
132. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22:403-8. (Pubitemid 29106894)
133. Caballero AE, Bousquet-Santos K, Robles-Osorio L, et al. Overweight Latino children and adolescents have marked endothelial dysfunction and subclinical vascular inflammation in association with excess body fat and insulin resistance. Diabetes Care 2008;31:576-82.
134. Shah AS, Dolan LM, Kimball TR, et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. J Clin Endocrinol Metabol 2009;94:3740-5.
135. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90. (Pubitemid 37430605)
136. Short KR, Blackett PR, Gardner AW, et al. Vascular health in children and adolescents: effects of obesity and diabetes. Vasc Health Risk Manag 2009;5:973-90